05 / K-ECO BIO 10 · PIPELINE
GRBM's flagship cash-cow pipeline. A 12-week VPMI process converts even ginseng's precursor components into rare ginsenosides, turning a traditional medicinal plant into a high-value lifelong bio-metabolome.
In plain words
Ginseng is a premium plant consumers around the world already understand. Yet in nature its pharmacological components take hundreds of years to mature, the ginsenoside content varies widely between plants so industrial yield is inconsistent, some components are poorly absorbed, and bioconversion can create isomers.
GINSENG GRBM solves these problems with a 12-week VPMI eco-bio metabolic process. The interaction of fresh ginseng, VPMI-CM and Vital Probiotics that have acquired ginseng's genetic information converts even ginseng's precursors into advanced pharmacological compounds, creating in particular a rare-ginsenoside spectrum centred on G-M12 (PPDol).
Its value is not in a single ginseng product. It lies in the combination of four things: ① a premium consumer cash cow, ② a high-value ginsenoside B2B ingredient platform, ③ a value ladder by purification stage from QL1 to QL5, and ④ a technology, data and market validation model for the whole GRBM platform.
FIVE STRUCTURAL WEAKNESSES
The longer ginseng lives, the more it advances its ginsenosides into rarer components. Wild mountain ginseng hundreds of years old is hard to supply industrially and extremely expensive. Conventional processing and bioconversion methods that try to shorten this time can create isomers or toxic components, so a "gene-based ecological bio-technology" is needed.
Large differences between plants make it hard to produce high-purity pharmacological components stably. Conventional extraction only recovers what is already there, which limits the output of high-value components.
Climate change alters the microbial ecosystems living with plants. If the microbes living with ginseng mutate, new risks to human-application safety can arise, separate from the plant's outward growth.
Existing products have stayed as vitality products for healthy adults. Yet ginseng's historical value lies in being a medicinal plant that matters most to the frail, the convalescent, the ill and the elderly.
The most important components for absorption are G-M1 (Compound K) and G-M12 (PPDol), but they are rare. Absorption at the ordinary ginsenoside stage is put at under 1%, and under 6% even after conventional processing.
THE 12-WEEK SOLUTION
The heart of GINSENG GRBM is industrializing, through the 12-week VPMI-GINSENG process, the maturation of ginseng's pharmacological compounds that happens naturally over hundreds of years. Just as wild mountain ginseng more than 230 years old advances its ginsenosides into rare components to survive, VPMI reproduces that natural maturation.
| Component | Role |
|---|---|
| Ginseng | Korea's flagship premium medicinal plant resource |
| Ginseng Probiotics | Vital Probiotics that acquire ginseng's RNA information and metabolize its components |
| Ginseng Metabolome | The final metabolome combining the G-M12 Complex, rare ginsenosides, postbiotics and biogenics |
Ginseng GRBM is formed through the activity of L-Group and S-Group microbes that have acquired ginseng's RNA information, and is finally advanced by Lp-Group microbes. Once the Lp-Group exceeds 80%, a structure forms in which the main ginsenosides are converted and expanded into G-M12, Rk2, Rh2, M1, Rg5, Rg6, Rg3, Rh4 and more.
FOUR DIFFERENTIATORS
Chemical conversion or forced bioconversion carries the risk of toxic isomers. GINSENG GRBM advances components not by harsh chemical treatment or genetic manipulation but through the genetic interaction of ginseng and Vital Probiotics, designed to reduce the risk of isomer formation while widening the rare-ginsenoside spectrum.
Conventional extraction is an economy of recovering the ginsenosides already present. GINSENG GRBM converts even precursors into an advanced ginsenoside pool. This is not extraction economics but precursor-conversion economics.
G-M12 (PPDol), together with G-M1 (Compound K), is the key rare ginsenoside that can solve the absorption problem, and it also helps reduce the physiological burden of other ginsenosides. This makes a universal GINSENG GRBM possible.
When component advancement, lower toxicity risk, better absorption and quality standardization combine, it can extend into a lifelong bio-healthcare ingredient for the fetus, infants, children, adolescents, adults and the elderly.
| Item | Value |
|---|---|
| Long-term ginseng processing target | 10,000 tonnes a year |
| Conventional ginsenoside extraction rate | About 1.0% |
| VPMI-GRBM generation and extraction rate | 2.67% on average |
| Conventional extraction output | About 100 tonnes |
| VPMI-GRBM output | About 267 tonnes (about 167 tonnes more) |
It is a three-layer bio-metabolome system in which rare ginsenosides, postbiotics and bio-information molecules work together.
THREE-LAYER BIO-METABOLOME
At its core are advanced phytochemicals such as G-M12, M1, Rk1/2/3/4, Rh1/2/3/4 and Rg3/4/5/6, and a rare-ginsenoside spectrum.
It also contains a postbiotic matrix such as the lactic–acetic compound organic acids made by Vital Probiotics.
A bio-information layer containing miRNA, bacteriocins and especially plantaricin. The developer believes it will work as a key element of future bio-medicine.
Component conversion data — HPLC data comparing raw six-year-old ginseng with the VPMI-GINSENG metabolome show different component peaks. VPMI-GINSENG does not merely extract ginseng; it restructures and widens the ginsenoside spectrum. The expansion of the spectrum is being confirmed by UPLC-QTOF analysis.
Cell compatibility data — In HaCaT and RAW264.7 cell experiments, an ordinary green bio-extract showed cytotoxic responses as the dose rose, while GRBM made with VPMI technology induced cell-regeneration responses up to a certain level. These are the company's internal cell experiments, and third-party validation is required for regulatory or clinical claims.
GINSENG GRBM is not approached with one price and one market. Markets, regulation and revenue models differ by purification level. Pharmaceutical application of QL5 presupposes separate non-clinical, clinical, GMP and approval procedures.
| Level | Definition | Main market | Revenue character |
|---|---|---|---|
| QL1 | Metabolized raw material | Premium foods, concentrates, service ingredients | Fast cash flow |
| QL2 | Separation of solids and metabolized liquid | Refined liquid, drinks, powders, smoothies, cosmetic ingredients | Recurring revenue |
| QL3 | First separation of solids into ginsenosides, bio-substances and genetic material | Ginsenoside-rich fractions, B2B ingredients | High-margin ingredients |
| QL4 | Regrouping of separated substances into similar clusters | G-M12 Complex, Rk/Rh clusters, rare-ginsenoside complexes | Premium B2B and licensing |
| QL5 | Component-by-component separation and high-purity (95%+) refinement | High-purity G-M12, research reference standards, MHM-PI candidates | IP and bio-candidate value |
Premium validation in Korea with PANAX GRBM GINSENG 50ml and MFB GINSENG 250ml — securing price acceptance, repurchase rates, felt responses, safety data and batch standardization
An aluminium-can drink that uses saponin-based natural sparkle to drive high-frequency repeat purchases and platform awareness
Becoming the core ingredient of Low, Middle, High and Holon Level services, turning product revenue into service, subscription and data revenue
Supplying QL3–QL4 fractions and the G-M12 Complex to global functional food, beverage, cosmetics and medical-nutrition companies
Developing high-purity G-M12 into research reference standards and MHM-PI candidates, securing pharma and bio co-research and licence-out opportunities
GINSENG GRBM turns Korea's most trusted medicinal plant into a QL1–QL5 value ladder built on 12-week precursor conversion, creating short-term cash flow, premium B2B ingredient revenue and long-term bio-candidate options at once.
Complete Proposal, Chapter 11 "GRBM Flagship Pipeline"
Yields, absorption and processing volumes are internal company figures and long-term assumptions, to be confirmed with analytical methods, batch data and bioavailability assessments. Cell experiments are internal company data. Source: research by the developer (Wooyoung Nam).
PARTNERSHIP · INVESTMENT
After signing an NDA you can review the materials, then verify the original records and the process in person during on-site due diligence in Uljin, Gyeongsangbuk-do, Korea.
